We are live on ! Find out more
IKT icon

Inhibikase Therapeutics

5 hedge funds and large institutions have $936K invested in Inhibikase Therapeutics in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.22% more ownership

Funds ownership: 0%0.22% (+0.22%)

Holders
5
Holders Change
+5
Holders Change %
% of All Funds
0.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$690K +$845K +16,667 New
ZCA
2
Zeke Capital Advisors
Pennsylvania
$130K +$159K +3,133 New
MS
3
Maven Securities
Jersey
$79K +$92.9K +1,833 New
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$35K +$42.2K +833 New
NFSG
5
Newbridge Financial Services Group
Florida
$2K +$2.13K +42 New

IKT Hedge Fund Activity: Q4 2020 in Review

5 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2020, worth a combined $936K.

Buyers outnumbered sellers: 5 funds opened new IKT positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $845K.

  • 5 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $936K of Inhibikase Therapeutics stock for Q4 2020.
  • 5 funds opened new Inhibikase Therapeutics positions in Q4 2020 and 0 closed out, a net change of +5 holders.
  • The largest Inhibikase Therapeutics buyer in Q4 2020 was Fidelity Investments, an estimated $845K added.

Based on aggregated 13F filings for Q4 2020.